Skip to main content

Ezetimibe as lipid-lowering therapy for patients receiving HAART

Background

Dyslipidaemia in HIV has been linked with both a cytokine-driven lipid metabolism re-arrangement in significant viraemia, and with the use of highly-active antiretroviral therapy (HAART), especially protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Methods

This study was a retrospective review, evaluating the efficacy and safety of Ezetimibe in our cohort of HIV-positive patients stable on HAART with dyslipidaemia. Out of the 29 such individuals prescribed 10 mg Ezetimibe once daily, 17 received it in addition to a statin, and 12 received it as a direct replacement for a statin.

Summary of results

Prior to initiation of Ezetimibe, median serum total cholesterol and triglyceride levels were 6.3 mmol/l (range: 3.6–10.7) and 2.9 mmol/l (range: 0.54–13.02), respectively. Review of the lipid profiles of the cohort after 12 weeks of Ezetimibe therapy revealed (see data in Figure 1). Two individuals discontinued Ezetimibe prematurely.

Conclusion

These results suggest that Ezetimibe may have an important role as an effective therapy for HAART-induced dyslipidaemia.

figure 1

Figure 1

References

  1. Coll B, et al: Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS. 2006, 20: 1675-7.

    PubMed  CAS  Article  Google Scholar 

  2. Negredo E, et al: Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS. 2006, 20: 2159-64.

    PubMed  CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Asghar, A., Bower, M., Holmes, P. et al. Ezetimibe as lipid-lowering therapy for patients receiving HAART. JIAS 11, P248 (2008). https://doi.org/10.1186/1758-2652-11-S1-P248

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1758-2652-11-S1-P248

Keywords

  • Lipid
  • Cholesterol
  • Protease Inhibitor
  • Total Cholesterol
  • Lipid Metabolism